Skip to content

33-105 : Drug Use-Results Survey of OPDIVO

33-105 : Drug Use-Results Survey of OPDIVO (Cancer of Unknown Primary)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT2041240121
Enrollment
100
Registered
2024-11-08
Start date
2022-07-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer of unknown primary

Interventions

None listed

Sponsors

Nakao Takafumi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with cancer of unknown primary, who have recieved OPDIVO for the first time

Exclusion criteria

Exclusion criteria: Patients who have received OPDIVO previously

Design outcomes

Primary

MeasureTime frame
[Safety] a) Occurrence status of adverse drug reactions and infections b) Adverse events

Contacts

Public ContactTakafumi Nakao

Ono Pharmaceutical Co.,LTD

pms_contact_ml@ono-pharma.com+81-6-6222-5501

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Aug 28, 2026